$115.2 M

EVOK Mkt cap, 23-Sept-2020
Evoke Pharma Net income (Q2, 2020)-7 M
Evoke Pharma EBIT (Q2, 2020)-7 M
Evoke Pharma Cash, 30-Jun-20208 M
Evoke Pharma EV109.3 M

Evoke Pharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

957.0k10.0m8.2m7.0m7.1m4.1m3.4m

General and administrative expense

1.6m3.2m3.7m3.6m4.1m3.9m3.7m

Operating expense total

2.6m13.2m11.8m10.5m11.2m8.0m7.2m

EBIT

(2.6m)(13.2m)(11.8m)(10.5m)(11.2m)(8.0m)(7.2m)

Interest expense

159.9k107.8k268.0k6.5k15.2k28.8k

Net Income

(2.8m)(13.2m)(12.1m)(10.7m)(12.2m)(7.6m)(7.1m)

Evoke Pharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.2m14.2m8.7m9.0m7.7m5.3m5.7m

Accounts Receivable

Prepaid Expenses

234.3k931.5k833.3k251.0k329.2k581.7k

Inventories

Current Assets

24.4m15.2m9.5m9.3m7.9m5.6m6.2m

Total Assets

25.0m15.3m9.5m9.3m7.9m5.7m6.4m

Accounts Payable

284.9k1.0m927.6k478.2k1.0m476.2k1.0m

Short-term debt

1.4m150.4k146.1k146.1k138.5k

Current Liabilities

2.3m1.9m1.8m1.4m2.1m1.6m2.0m

Long-term debt

1.5m4.2m4.2m4.2m

Total Debt

3.0m4.4m4.4m4.4m138.5k

Total Liabilities

3.8m6.1m6.1m5.5m5.8m1.6m

Common Stock

610.0611.0720.01.5k1.7k2.4k

Additional Paid-in Capital

43.9m45.1m51.5m62.6m73.2m82.6m90.1m

Retained Earnings

(35.9m)(48.1m)(58.8m)(71.0m)(78.6m)(85.7m)

Total Equity

21.2m9.2m3.5m3.8m2.2m4.0m4.4m

Debt to Equity Ratio

0.1 x0.5 x1.3 x1.2 x

Debt to Assets Ratio

0.1 x0.3 x0.5 x0.5 x

Financial Leverage

1.2 x1.7 x2.8 x2.5 x3.7 x1.4 x1.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

23.7m21.8m16.0m12.2m11.7m9.9m10.7m6.1m4.1m10.4m14.7m12.6m10.4m5.4m6.5m6.6m4.0m7.4m6.5m4.1m8.0m

Prepaid Expenses

176.2k888.9k1.1m858.1k716.6k935.9k764.7k499.3k425.2k171.5k587.9k334.7k167.4k83.7k439.0k219.5k109.7k775.6k387.8k193.9k

Current Assets

23.7m22.0m16.9m13.3m12.6m10.6m11.7m6.9m4.6m10.8m14.8m13.1m10.7m5.6m6.6m7.0m4.3m7.6m7.3m4.5m8.2m

Total Assets

23.7m22.6m17.0m13.4m12.6m10.6m11.7m6.9m4.6m10.8m14.8m13.2m10.8m5.6m6.6m7.0m4.4m7.6m7.3m4.6m8.3m

Accounts Payable

1.2m1.1m1.3m1.0m1.4m1.4m1.3m1.2m1.3m498.1k549.0k1.1m1.7m546.0k441.1k626.0k491.8k407.5k1.2m925.6k604.8k

Short-term debt

1.1m1.4m712.9k1.3m708.6k4.4m105.4k71.2k

Current Liabilities

2.6m2.9m1.8m1.7m2.5m3.2m2.0m2.4m6.2m1.0m1.1m1.9m2.6m1.2m1.3m1.6m1.3m1.3m2.2m1.7m6.6m

Long-term debt

1.9m1.2m3.7m3.1m4.4m3.7m2.0m

Total Debt

1.9m2.6m4.4m4.4m4.4m4.4m4.4m105.4k2.1m

Total Liabilities

4.5m4.1m1.9m1.7m6.2m6.3m6.4m6.1m6.2m6.1m6.9m6.4m8.7m1.2m1.3m1.6m8.6m

Common Stock

578.0610.0610.0611.0620.0631.0709.0724.0729.01.2k1.5k1.5k1.5k1.6k1.7k1.7k1.8k2.4k2.4k2.4k2.6k

Additional Paid-in Capital

40.3m44.1m44.4m44.7m45.9m47.0m50.7m52.0m52.7m62.0m71.8m72.3m72.8m77.4m80.7m82.3m83.6m89.0m89.5m90.4m94.1m

Retained Earnings

(29.2m)(33.0m)(39.5m)(42.7m)(45.4m)(51.3m)(54.3m)(57.3m)(63.9m)(65.5m)(70.7m)(73.0m)(75.3m)(76.8m)(80.6m)(82.7m)(84.3m)(87.5m)(94.5m)

Total Equity

19.2m18.5m15.2m11.7m6.4m4.3m5.3m757.2k(1.5m)4.7m7.9m6.8m2.1m4.4m5.4m5.4m3.1m6.3m5.2m2.9m(373.7k)

Debt to Equity Ratio

0.1 x1 x5.8 x-2.9 x

Debt to Assets Ratio

0.1 x0.4 x0.6 x0.9 x

Financial Leverage

1.2 x1.2 x1.1 x1.1 x2 x2.5 x2.2 x9.1 x-3 x2.3 x1.9 x1.9 x5.2 x1.3 x1.2 x1.3 x1.4 x1.2 x1.4 x1.6 x-22.1 x

Evoke Pharma Ratios

USDQ3, 2013

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x